Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery

Abstract

Safety data from the first 6 months of postmarketing experience with edoxaban did not identify any unforeseen safety signals, consistent with the known safety profile of edoxaban.